Humalog Mix25 Kwikpen (Insulin Lispro)

Humalog Mix25 Kwikpen is indicated for use in adults with diabetes who require both prandial and basal insulin coverage.

• Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen.
• Type 2 diabetes mellitus when oral agents no longer provide adequate glycaemic control.
• Adjunct therapy for patients transitioning from multiple daily injections to a simplified pen‑based regimen.
• Management of post‑prandial glucose excursions in combination with diet and exercise.
• Use in hospital or outpatient settings where rapid insulin action is needed.

• Insulin lispro is a recombinant insulin analog that differs from human insulin by two amino‑acid substitutions, reducing its tendency to form hexamers. After subcutaneous injection, the rapid‑acting component dissociates quickly, binding to insulin receptors on muscle and adipose tissue, activating the receptor tyrosine kinase pathway, and promoting GLUT‑4 translocation for glucose uptake. The protamine‑bound portion creates an intermediate‑acting depot, prolonging receptor activation and suppressing hepatic glucose production.

Like all insulin preparations, Humalog Mix25 Kwikpen may cause adverse reactions, which are generally classified by frequency and severity.

Common

• Hypoglycaemia (low blood glucose).
• Injection‑site pain, redness or swelling.
• Lipodystrophy at the injection site.
• Allergic skin reactions such as rash or itching.

Serious

• Severe hypoglycaemia with neuroglycopenic symptoms.
• Anaphylactic reaction or angio‑edema.
• Hypersensitivity leading to bronchospasm or urticaria.

Healthcare providers should consider several precautions when prescribing Humalog Mix25 Kwikpen to ensure safe and effective use.

• Assess renal and hepatic function, as impairment can alter insulin clearance.
• Educate patients on recognizing and treating hypoglycaemia promptly.
• Avoid use in patients with known hypersensitivity to insulin lispro or protamine.
• Adjust doses during periods of illness, reduced food intake, or increased physical activity.
• Pregnancy and lactation status should be evaluated; insulin may be required but dosing must be individualized.
• Store the pen at controlled room temperature and discard after the in‑use period indicated on the label.

Humalog Mix25 Kwikpen can interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogs without dose adjustment.
• Beta‑blockers that may mask hypoglycaemia symptoms.
• MAO‑inhibitors or tricyclic antidepressants that can potentiate insulin effects.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) – monitor for additive hypoglycaemia.
• Corticosteroids or thiazide diuretics – may raise blood glucose, requiring insulin dose increase.
• Alcohol consumption – can cause delayed hypoglycaemia, especially with bedtime dosing.